The British pharmaceutical giant AstraZeneca Plc will argue before Delaware’s Court of Chancery this week that claims it pushed biotech company Viela Bio Inc. into a sale with another drug company to avoid potential antitrust concerns are “fanciful allegations.”
Myasthenia Gravis Treatment Market Size, Share & Growth globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Second-Quarter 2023 Results: Net Sales of $945.0 Million, Representing Year-Over-Year Growth of 11% Excluding Inflammation Medicines GAAP Net Income of $127.1 Million; Adjusted EBITDA of.
First-Quarter 2023 Results: Net Sales of $832.1 Million GAAP Net Income of $54.7 Million; Adjusted EBITDA of $232.9 Million TEPEZZA® Net Sales of $405.3 Million . | May 3, 2023
The global antibody-mediated rejection prevention market is predicted to reach a valuation of US$ 89 million in 2023, with a compound annual growth rate (CAGR) of 16%, as per a recently published FMI report. Over the last decade, the complement system has emerged as an important constituent of the AMR market.Technol.